# US 2025/0084157 A1 · Antibody based reagents that specifically recognize toxic oligomeric forms of tau

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084157 A1
- Document ID: US20250084157A1
- Status: Published application
- Kind: A1
- Application number: 18/829,906
- Filed: 2024-09-10
- Published: 2025-03-13
- Earliest claimed: 2012-10-12
- Assignees: Arizona Board of Regents on behalf of Arizona State University
- Applicants: Arizona Board of Regents On Behalf of Arizona State University
- Inventors: Michael SIERKS; Huilai TIAN
- Web page: https://patentgrep.com/patent/US20250084157A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/005: {constructed by phage libraries}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/62: comprising only variable region components
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2800/28: Neurological disorders
- G01N 2800/2814: Dementia; Cognitive disorders
- G01N 2800/2821: Alzheimer
- G01N 2800/7047: Fibrils-Filaments-Plaque formation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.

## Claims

### Claim 1

A binding molecule comprising six complementarity determining regions (CDRs) having amino acid sequences NFGMH (SEQ ID NO: 63), IISYDASSEYYADSVKG (SEQ ID NO: 64), and KDGRSGSYYYGDY (SEQ ID NO: 65), RASQDFRNWLA (SEQ ID NO: 66), GASTLQN (SEQ ID NO: 67), and QQAHSFPPT (SEQ ID NO: 68), of SEQ ID NO: 17.

### Claim 2 (depends on 1)

The binding molecule of claim 1, wherein the binding molecule has 80% sequence identity to SEQ ID NO: 17.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The binding molecule of claim 1, wherein the binding molecule binds to oligomeric tau and does not bind monomeric tau, fibrillar tau or non-disease associated forms of tau.

### Claim 5 (depends on 1)

A method of inhibiting the aggregation of tau, the method comprising contacting a composition that comprises tau oligomers with the binding molecule of claim 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein said aggregation of tau is in a cell.

### Claim 7 (depends on 5)

The method of claim 5, wherein said contacting with the binding molecule decreases a rate of formation of tau aggregates as compared to said rate in the absence of the composition or the binding molecule.

### Claim 8 (depends on 5)

The method of claim 5, wherein the tau oligomers are dimeric or trimeric tau.

### Claim 9 (depends on 8)

The method of claim 8, wherein the tau oligomers are soluble.

### Claim 10 (depends on 5)

The method of claim 5, wherein the binding molecule binds to oligomeric tau and does not bind monomeric tau, fibrillary tau or non-disease associated forms of tau.

### Claim 11 (depends on 1)

A method of detecting the presence of tau in a physiological sample, the method comprising
contacting a physiological sample with the binding molecule of claim 1; and
determining the binding of the binding molecule with said physiological sample wherein binding of the binding molecule to said physiological sample is indicative of the presence of tau oligomers in said physiological sample, wherein said presence of said tau oligomers is indicative of early stage Alzheimer's disease (AD), frontotemporal dementia, other tauopathies, or neurodegeneration following traumatic brain injury.

### Claim 12 (depends on 11)

The method of claim 11, wherein the physiological sample is brain tissue, serum, cerebrospinal fluid (CSF), blood, urine or saliva.

### Claim 13 (depends on 1)

A method of inhibiting the aggregation of tau in a physiological sample, the method comprising contacting a composition that comprises tau oligomers with the binding molecule of claim 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein said aggregation of tau is in a cell.

### Claim 15 (depends on 13)

The method of claim 13, wherein said contacting with the binding molecule decreases a rate of formation of tau aggregates as compared to said rate in the absence of the composition or the binding molecule.

### Claim 16 (depends on 13)

The method of claim 13, wherein the tau oligomers are dimeric or trimeric tau.

### Claim 17 (depends on 16)

The method of claim 16, wherein the tau oligomers are soluble.

### Claim 18 (depends on 13)

The method of claim 13, wherein the binding molecule binds to oligomeric tau and does not bind monomeric tau, fibrillary tau or non-disease associated forms of tau.

### Claim 19 (depends on 1)

A method inhibiting the accumulation of tau in the brain of a mammal, the method comprising administering to said mammal a composition comprising the binding molecule of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the binding molecule binds to oligomeric tau and does not bind monomeric tau, fibrillary tau or non-disease associated forms of tau.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1, 19)

The method of claim 19, wherein the binding molecule of claim 1 is administered to said mammal following a traumatic brain injury.
